vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and ABVC BIOPHARMA, INC. (ABVC). Click either name above to swap in a different company.
AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $796.0K, roughly 56.4× ABVC BIOPHARMA, INC.). AbCellera Biologics Inc. runs the higher net margin — -19.9% vs -256.6%, a 236.7% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 104.5%). Over the past eight quarters, ABVC BIOPHARMA, INC.'s revenue compounded faster (1041.5% CAGR vs 112.3%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
ABVC Biopharma Inc. is a clinical-stage biopharmaceutical enterprise focused on developing innovative therapies for unmet medical needs, with core areas including oncology, ophthalmology, and central nervous system disorders. It operates across North American and Asian markets, advancing multiple proprietary drug candidates through clinical development phases.
ABCL vs ABVC — Head-to-Head
Income Statement — Q4 2025 vs Q3 2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $796.0K |
| Net Profit | $-8.9M | $-2.0M |
| Gross Margin | — | 100.0% |
| Operating Margin | -63.7% | -246.8% |
| Net Margin | -19.9% | -256.6% |
| Revenue YoY | 788.4% | 104.5% |
| Net Profit YoY | 73.9% | -417.4% |
| EPS (diluted) | $-0.03 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | — | ||
| Q3 25 | $9.0M | $796.0K | ||
| Q2 25 | $17.1M | — | ||
| Q1 25 | $4.2M | — | ||
| Q4 24 | $5.0M | $2.0K | ||
| Q3 24 | $6.5M | $389.3K | ||
| Q2 24 | $7.3M | $117.1K | ||
| Q1 24 | $10.0M | $1.2K |
| Q4 25 | $-8.9M | — | ||
| Q3 25 | $-57.1M | $-2.0M | ||
| Q2 25 | $-34.7M | — | ||
| Q1 25 | $-45.6M | — | ||
| Q4 24 | $-34.2M | $-731.6K | ||
| Q3 24 | $-51.1M | $-394.8K | ||
| Q2 24 | $-36.9M | $-942.3K | ||
| Q1 24 | $-40.6M | $-2.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | 100.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 100.0% | ||
| Q3 24 | — | 99.9% | ||
| Q2 24 | — | 99.8% | ||
| Q1 24 | — | 77.0% |
| Q4 25 | -63.7% | — | ||
| Q3 25 | -851.8% | -246.8% | ||
| Q2 25 | -290.2% | — | ||
| Q1 25 | -1479.6% | — | ||
| Q4 24 | -1441.0% | -35837.4% | ||
| Q3 24 | -1439.4% | -77.7% | ||
| Q2 24 | -1276.2% | -734.2% | ||
| Q1 24 | -551.5% | -235539.8% |
| Q4 25 | -19.9% | — | ||
| Q3 25 | -637.8% | -256.6% | ||
| Q2 25 | -203.3% | — | ||
| Q1 25 | -1077.2% | — | ||
| Q4 24 | -677.6% | -37211.3% | ||
| Q3 24 | -785.4% | -101.4% | ||
| Q2 24 | -504.3% | -804.4% | ||
| Q1 24 | -408.0% | -235203.2% |
| Q4 25 | $-0.03 | — | ||
| Q3 25 | $-0.19 | $-0.09 | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | $-0.11 | $-0.02 | ||
| Q3 24 | $-0.17 | $-0.03 | ||
| Q2 24 | $-0.13 | $-0.08 | ||
| Q1 24 | $-0.14 | $-0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $257.2K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $12.1M |
| Total Assets | $1.4B | $21.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | — | ||
| Q3 25 | $83.2M | $257.2K | ||
| Q2 25 | $92.4M | — | ||
| Q1 25 | $159.3M | — | ||
| Q4 24 | $156.3M | $313.1K | ||
| Q3 24 | $126.6M | $208.2K | ||
| Q2 24 | $148.3M | $200.0K | ||
| Q1 24 | $123.6M | $106.4K |
| Q4 25 | $966.9M | — | ||
| Q3 25 | $964.0M | $12.1M | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.1B | $1.2M | ||
| Q3 24 | $1.1B | $1.6M | ||
| Q2 24 | $1.1B | $1.8M | ||
| Q1 24 | $1.1B | $1.7M |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $21.2M | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.4B | $7.5M | ||
| Q3 24 | $1.4B | $7.8M | ||
| Q2 24 | $1.4B | $8.0M | ||
| Q1 24 | $1.5B | $8.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $-964.7K |
| Free Cash FlowOCF − Capex | $-44.6M | — |
| FCF MarginFCF / Revenue | -99.4% | — |
| Capex IntensityCapex / Revenue | 21.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | — | ||
| Q3 25 | $-52.6M | $-964.7K | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-11.6M | — | ||
| Q4 24 | $-8.0M | $-702.1K | ||
| Q3 24 | $-28.9M | $60.2K | ||
| Q2 24 | $-30.0M | $-211.4K | ||
| Q1 24 | $-41.7M | $-955.8K |
| Q4 25 | $-44.6M | — | ||
| Q3 25 | $-61.5M | — | ||
| Q2 25 | $-45.8M | — | ||
| Q1 25 | $-22.2M | — | ||
| Q4 24 | $-23.6M | — | ||
| Q3 24 | $-47.4M | — | ||
| Q2 24 | $-50.1M | — | ||
| Q1 24 | $-65.8M | — |
| Q4 25 | -99.4% | — | ||
| Q3 25 | -687.0% | — | ||
| Q2 25 | -267.9% | — | ||
| Q1 25 | -524.0% | — | ||
| Q4 24 | -468.0% | — | ||
| Q3 24 | -728.4% | — | ||
| Q2 24 | -683.8% | — | ||
| Q1 24 | -661.5% | — |
| Q4 25 | 21.9% | — | ||
| Q3 25 | 99.7% | — | ||
| Q2 25 | 78.2% | — | ||
| Q1 25 | 251.1% | — | ||
| Q4 24 | 309.6% | — | ||
| Q3 24 | 284.6% | — | ||
| Q2 24 | 274.6% | — | ||
| Q1 24 | 242.5% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
